{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:35:27Z","timestamp":1783038927321,"version":"3.54.6"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T00:00:00Z","timestamp":1513209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/aps.2017.167","type":"journal-article","created":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T14:56:43Z","timestamp":1513263403000},"page":"1189-1196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure"],"prefix":"10.1038","volume":"39","author":[{"given":"Peter","family":"Jirak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dzeneta","family":"Fejzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Paar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Wernly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudin","family":"Pistulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilonka","family":"Rohm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta C","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Christian","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lichtenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atilla","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kretzschmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,14]]},"reference":[{"key":"92_CR1","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.ehj.2004.06.038","volume":"25","author":"GS Bleumink","year":"2004","unstructured":"Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: The Rotterdam Study. Eur Heart J 2004; 25: 1614\u20139.","journal-title":"Eur Heart J"},{"key":"92_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891\u2013975.","journal-title":"Eur J Heart Fail"},{"key":"92_CR3","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","volume":"93","author":"A Mosterd","year":"2007","unstructured":"Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93: 1137\u201346.","journal-title":"Heart"},{"key":"92_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10741-015-9506-7","volume":"20","author":"CL Lekavich","year":"2015","unstructured":"Lekavich CL, Barksdale DJ, Neelon V, Wu JR. Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review. Heart Fail Rev 2015; 20: 643\u201353.","journal-title":"Heart Fail Rev"},{"key":"92_CR5","first-page":"30","volume":"52","author":"E Oikonomou","year":"2011","unstructured":"Oikonomou E, Tousoulis D, Siasos G, Zaromitidou M, Papavassiliou AG, Stefanadis C. The role of inflammation in heart failure: new therapeutic approaches. Hellenic J Cardiol 2011; 52: 30\u201340.","journal-title":"Hellenic J Cardiol"},{"key":"92_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000338166","volume":"122","author":"L Gullestad","year":"2012","unstructured":"Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P. Inflammatory cytokines in heart failure: mediators and markers. Cardiology 2012; 122: 23\u201335.","journal-title":"Cardiology"},{"key":"92_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1161\/HYPERTENSIONAHA.115.05627","volume":"66","author":"H Peng","year":"2015","unstructured":"Peng H, Sarwar Z, Yang XP, Peterson EL, Xu J, Janic B, et al. Profibrotic role for interleukin-4 in cardiac remodeling and dysfunction. Hypertension 2015; 66: 582\u20139.","journal-title":"Hypertension"},{"key":"92_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10741-009-9140-3","volume":"15","author":"B Bozkurt","year":"2010","unstructured":"Bozkurt B, Mann DL, Deswal A. Biomarkers of inflammation in heart failure. Heart Fail Rev 2010; 15: 331\u201341.","journal-title":"Heart Fail Rev"},{"key":"92_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cca.2014.09.021","volume":"443","author":"B Dieplinger","year":"2015","unstructured":"Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta 2015; 443: 57\u201370.","journal-title":"Clin Chim Acta"},{"key":"92_CR10","first-page":"245","volume":"248","author":"C Andersson","year":"2016","unstructured":"Andersson C, Enserro D, Sullivan L, Wang TJ. Januzzi JL Jr, Benjamin EJ, et al. Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study. Atherosclerosis 2016; 248: 245\u201351.","journal-title":"Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study. Atherosclerosis"},{"key":"92_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cca.2014.10.046","volume":"443","author":"AC Pouleur","year":"2015","unstructured":"Pouleur AC. Which biomarkers do clinicians need for diagnosis and management of heart failure with reduced ejection fraction? Clin Chim Acta 2015; 443: 9\u201316.","journal-title":"Clin Chim Acta"},{"key":"92_CR12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/heartjnl-2012-303325","volume":"99","author":"M Reiter","year":"2013","unstructured":"Reiter M, Twerenbold R, Reichlin T, Mueller M, Hoeller R, Moehring B, et al. Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction. Heart 2013; 99: 708\u2013714.","journal-title":"Heart"},{"key":"92_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1365-2796.2010.02252.x","volume":"268","author":"J Eugen-Olsen","year":"2010","unstructured":"Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010; 268: 296\u2013308.","journal-title":"J Intern Med"},{"key":"92_CR14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nrd2660","volume":"7","author":"R Kakkar","year":"2008","unstructured":"Kakkar R, Lee RT. The IL-33\/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008; 7: 827\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"92_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11897-012-0113-9","volume":"9","author":"KC Wollert","year":"2012","unstructured":"Wollert KC, Kempf T. Growth differentiation factor 15 in heart failure: an update. Curr Heart Fail Rep 2012; 9: 337\u201345.","journal-title":"Curr Heart Fail Rep"},{"key":"92_CR16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.18295\/2075-0528.2796","volume":"9","author":"HA Al-Hadi","year":"2009","unstructured":"Al-Hadi HA, Fox KA. Cardiac markers in the early diagnosis and management of patients with acute coronary syndrome. Sultan Qaboos Univ Med J 2009; 9: 231\u201346.","journal-title":"Sultan Qaboos Univ Med J"},{"key":"92_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejim.2017.05.027","volume":"44","author":"M Lichtenauer","year":"2017","unstructured":"Lichtenauer M, Jirak P, Wernly B, Paar V, Rohm I, Jung C, et al. A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure. Eur J Intern Med 2017; 44: 31\u20138.","journal-title":"Eur J Intern Med"},{"key":"92_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1155\/2009\/504294","volume":"27","author":"M Thuno","year":"2009","unstructured":"Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009; 27: 157\u201372.","journal-title":"Dis Markers"},{"key":"92_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.atherosclerosis.2011.01.049","volume":"216","author":"T Sehestedt","year":"2011","unstructured":"Sehestedt T, Lyngbak S, Eugen-Olsen J, Jeppesen J, Andersen O, Hansen TW, et al. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis 2011; 216: 237\u201343.","journal-title":"Atherosclerosis"},{"key":"92_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2147\/VHRM.S90383","volume":"12","author":"U Muller-Werdan","year":"2016","unstructured":"Muller-Werdan U, Stockl G, Werdan K. Advances in the management of heart failure: the role of ivabradine. Vasc Health Risk Manag 2016; 12: 453\u201370.","journal-title":"Vasc Health Risk Manag"},{"key":"92_CR21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","volume":"372","author":"K Fox","year":"2008","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 817\u201321.","journal-title":"Lancet"},{"key":"92_CR22","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","volume":"376","author":"M Bohm","year":"2010","unstructured":"Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886\u201394.","journal-title":"Lancet"},{"key":"92_CR23","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/j.amjcard.2016.08.089","volume":"118","author":"JS Borer","year":"2016","unstructured":"Borer JS, Deedwania PC, Kim JB, Bohm M. Benefits of heart rate slowing with ivabradine in patients with systolic heart failure and coronary artery disease. Am J Cardiol 2016; 118: 1948\u201353.","journal-title":"Am J Cardiol"},{"key":"92_CR24","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/CIRCRESAHA.109.208041","volume":"106","author":"D DiFrancesco","year":"2010","unstructured":"DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res 2010; 106: 434\u201346.","journal-title":"Circ Res"},{"key":"92_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrcardio.2009.47","volume":"6","author":"R de Silva","year":"2009","unstructured":"de Silva R, Fox KM. Angina: Ivabradine for treatment of stable angina pectoris. Nat Rev Cardiol 2009; 6: 329\u201330.","journal-title":"Nat Rev Cardiol"},{"key":"92_CR26","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875\u201385.","journal-title":"Lancet"},{"key":"92_CR27","doi-asserted-by":"crossref","unstructured":"Beautiful Study Group, Ferrari R, Ford I, Fox K, Steg PG, Tendera M. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology 2008; 110: 271\u201382.","DOI":"10.1159\/000112412"},{"key":"92_CR28","doi-asserted-by":"publisher","first-page":"6949320","DOI":"10.1155\/2016\/6949320","volume":"2016","author":"I Rohm","year":"2016","unstructured":"Rohm I, Kretzschmar D, Pistulli R, Franz M, Schulze PC, Stumpf C, et al. Impact of ivabradine on inflammatory markers in chronic heart failure. J Immunol Res 2016; 2016: 6949320.","journal-title":"J Immunol Res"},{"key":"92_CR29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1378\/chest.98.3.699","volume":"98","author":"A Ardehali","year":"1990","unstructured":"Ardehali A, Ports TA. Myocardial oxygen supply and demand. Chest 1990; 98: 699\u2013705.","journal-title":"Chest"},{"key":"92_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11517-008-0314-2","volume":"46","author":"JP van den Wijngaard","year":"2008","unstructured":"van den Wijngaard JP, Kolyva C, Siebes M, Dankelman J, van Gemert MJ, Piek JJ, et al. Model prediction of subendocardial perfusion of the coronary circulation in the presence of an epicardial coronary artery stenosis. Med Biol Eng Comput 2008; 46: 421\u201332.","journal-title":"Med Biol Eng Comput"},{"key":"92_CR31","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1161\/CIRCULATIONAHA.115.018094","volume":"133","author":"MA Psotka","year":"2016","unstructured":"Psotka MA, Teerlink JR. Ivabradine: role in the chronic heart failure armamentarium. Circulation 2016; 133: 2066\u201375.","journal-title":"Circulation"},{"key":"92_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ijcard.2012.04.076","volume":"158","author":"A Dominguez-Rodriguez","year":"2012","unstructured":"Dominguez-Rodriguez A, Consuegra-Sanchez L, Blanco-Palacios G, Abreu-Gonzalez P, Sanchez-Grande A, Bosa-Ojeda F, et al. Anti-inflammatory effects of ivabradine in patients with acute coronary syndrome: a pilot study. Int J Cardiol 2012; 158: 160\u20132.","journal-title":"Int J Cardiol"},{"key":"92_CR33","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/clc.22183","volume":"36","author":"L Sargento","year":"2013","unstructured":"Sargento L, Satendra M, Longo S, Lousada N, Palma dos Reis R. Early NT-proBNP decrease with ivabradine in ambulatory patients with systolic heart failure. Clin Cardiol 2013; 36: 677\u201382.","journal-title":"Clin Cardiol"},{"key":"92_CR34","doi-asserted-by":"publisher","first-page":"501","DOI":"10.5603\/CJ.a2015.0012","volume":"22","author":"S Ordu","year":"2015","unstructured":"Ordu S, Yildiz BS, Alihanoglu YI, Ozsoy A, Tosun M, Evrengul H, et al. Effects of ivabradine therapy on heart failure biomarkers. Cardiol J 2015; 22: 501\u20139.","journal-title":"Cardiol J"},{"key":"92_CR35","first-page":"776","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J. Casey DE Jr, Colvin MM, et al. 2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017; 70: 776\u2013803.","journal-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer"},{"key":"92_CR36","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.hfc.2009.04.006","volume":"5","author":"T Kempf","year":"2009","unstructured":"Kempf T, Wollert KC. Growth-differentiation factor-15 in heart failure. Heart Fail Clin 2009; 5: 537\u201347.","journal-title":"Heart Fail Clin"},{"key":"92_CR37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10741-016-9533-z","volume":"21","author":"A Briasoulis","year":"2016","unstructured":"Briasoulis A, Androulakis E, Christophides T, Tousoulis D. The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Fail Rev 2016; 21: 169\u201376.","journal-title":"Heart Fail Rev"},{"key":"92_CR38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jchf.2013.04.012","volume":"1","author":"P Carson","year":"2013","unstructured":"Carson P, Wertheimer J, Miller A, O'Connor CM, Pina IL, Selzman C, et al. The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results. JACC Heart Fail 2013; 1: 400\u20138.","journal-title":"JACC Heart Fail"},{"key":"92_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.cardfail.2006.10.014","volume":"13","author":"T Niizeki","year":"2007","unstructured":"Niizeki T, Takeishi Y, Arimoto T, Takabatake N, Nozaki N, Hirono O, et al. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. J Card Fail 2007; 13: 120\u20137.","journal-title":"J Card Fail"},{"key":"92_CR40","doi-asserted-by":"publisher","first-page":"15314","DOI":"10.3390\/molecules181215314","volume":"18","author":"MM Ciccone","year":"2013","unstructured":"Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, et al. A novel cardiac bio-marker: ST2: a review. Molecules 2013; 18: 15314\u201328.","journal-title":"Molecules"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps2017167","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2017167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/aps.2017.167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/aps2017167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T20:04:36Z","timestamp":1751141076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps2017167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,14]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["92"],"URL":"https:\/\/doi.org\/10.1038\/aps.2017.167","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,14]]},"assertion":[{"value":"9 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}